Detalhe da pesquisa
1.
Communication partners experiences of communicating with adults with severe/profound intellectual disability through augmentative and alternative communication: A mixed methods systematic review.
J Intellect Disabil
; 27(4): 1107-1134, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35850628
2.
Acute service and disability service providers experiences of joint working to improve health care experiences of people with an intellectual disability compared to non-joint working: A mixed-method systematic review.
J Intellect Disabil
; : 17446295231209345, 2023 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864518
3.
Determining the need for a breast cancer awareness educational intervention for women with mild/moderate levels of intellectual disability: A qualitative descriptive study.
Eur J Cancer Care (Engl)
; 31(4): e13590, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35393746
4.
Defining breast cancer awareness and identifying barriers to breast cancer awareness for women with an intellectual disability: A review of the literature.
J Intellect Disabil
; : 1744629521999548, 2021 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769130
5.
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med
; 372(1): 30-9, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25399551
6.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
N Engl J Med
; 371(20): 1877-88, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25265492
7.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med
; 367(2): 107-14, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22663011
8.
Factors influencing communication partners of persons with severe/profound intellectual disability use of augmentative and alternative communication: an integrative review.
Disabil Rehabil Assist Technol
; : 1-17, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38323877
9.
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Lancet
; 380(9839): 358-65, 2012 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22735384
10.
Can standardized diagnostic assessment be a useful adjunct to clinical assessment in child mental health services? A randomized controlled trial of disclosure of the Development and Well-Being Assessment to practitioners.
Soc Psychiatry Psychiatr Epidemiol
; 48(4): 583-93, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22886389
11.
[The work placement for developing skills]. / Le parcours de stage pour développer ses compétences.
Rev Infirm
; (191): 20-1, 2013 May.
Artigo
em Francês
| MEDLINE | ID: mdl-23776978
12.
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Lancet Oncol
; 13(8): 827-37, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22759480
13.
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 13(11): 1087-95, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23051966
14.
Targeting the IL1ß Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses.
Cancer Immunol Res
; 11(6): 777-791, 2023 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37040466
15.
Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors.
BMC Cancer
; 12: 405, 2012 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-22967017
16.
Non-verbal communication between Registered Nurses Intellectual Disability and people with an intellectual disability: an exploratory study of the nurse's experiences. Part 2.
J Intellect Disabil
; 16(2): 97-108, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22433478
17.
Non-verbal communication between Registered Nurses Intellectual Disability and people with an intellectual disability: an exploratory study of the nurse's experiences. Part 1.
J Intellect Disabil
; 16(1): 61-75, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22415748
18.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS One
; 17(10): e0276211, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36215283
19.
Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
Cancer
; 117(21): 5013-20, 2011 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21456017
20.
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Chin J Cancer
; 30(5): 327-35, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21527065